PI3K/mTOR therapies, Companion Diagnostics

Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for cancer by leveraging its advanced cellular analysis platform. This platform is designed to uncover complex oncogenic activities that traditional molecular tests may miss, allowing for the discovery of previously undetectable cancer drivers. One of the company's lead candidates, gedatolisib, is a dual inhibitor of the PI3K and mTOR pathways, which are critical in many cancer types. By providing insights into these oncogenic pathways, Celcuity aims to create new potential applications for targeted therapies, ultimately offering hope to cancer patients through innovative treatment options.

The company is currently conducting clinical trials, including the CELC-G-201 Phase 1/2 study, which evaluates the combination of gedatolisib with darolutamide, an androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC). This study aims to explore the simultaneous inhibition of the PI3K/mTOR and androgen receptor pathways to disrupt their complex interactions and inhibit tumor growth. By targeting these pathways, Celcuity seeks to provide effective treatment options for patients who have previously shown resistance to androgen receptor inhibitors, thereby enhancing the potential for improved patient outcomes in cancer therapy.

United States

Celcuity is a clinical stage biotechnology company that discovers previously undetectable cancer drivers and develops drugs to treat them.

Celcuity

Company Details